G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
HSP27 and HSP70: potentially oncogenic apoptosis inhibitors.
TL;DR: HSP27 and HSP70 may participate in oncogenesis, as suggested by the fact that overexpression of heat shock proteins can increase the tumorigenic potential of tumor cells.
Journal ArticleDOI
Autophagy in healthy aging and disease
Yahyah Aman,Yahyah Aman,Tomas Schmauck-Medina,Malene Hansen,Richard I. Morimoto,Anna Katharina Simon,Ivana Bjedov,Konstantinos Palikaras,Anne Simonsen,Anne Simonsen,Terje Johansen,Nektarios Tavernarakis,Nektarios Tavernarakis,David C. Rubinsztein,Linda Partridge,Linda Partridge,Guido Kroemer,John Labbadia,Evandro Fei Fang +18 more
TL;DR: A recent review as discussed by the authors examines several emerging features of autophagy and postulates how they may be linked to aging as well as to the development and progression of disease, and discusses current preclinical evidence arguing for the use of auto-ophagy modulators as suppressors of age-related pathologies such as neurodegenerative diseases.
Journal ArticleDOI
Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein
Enyong Dai,Leng Han,Jiao Liu,Yangchun Xie,Guido Kroemer,Daniel J. Klionsky,Herbert J. Zeh,Rui Kang,Jing Wang,Daolin Tang,Daolin Tang +10 more
TL;DR: This work reports that extracellular KRASG12D is essential for pancreatic tumor-associated macrophage polarization and identifies it as a key mediator of cancer cell-macrophage communication, and provides a novel KRAS-targeted anticancer strategy.
Journal ArticleDOI
Mitochondrial gateways to cancer.
Lorenzo Galluzzi,Eugenia Morselli,Eugenia Morselli,Oliver Kepp,Oliver Kepp,Ilio Vitale,Ilio Vitale,Alice Rigoni,Alice Rigoni,Erika Vacchelli,Erika Vacchelli,Erika Vacchelli,Mickaël Michaud,Mickaël Michaud,Hans Zischka,Maria Castedo,Maria Castedo,Guido Kroemer,Guido Kroemer +18 more
TL;DR: Several mechanisms by which mitochondria can contribute to malignant transformation and tumor progression are discussed.
Journal ArticleDOI
Natural and therapy-induced immunosurveillance in breast cancer
Guido Kroemer,Laura Senovilla,Lorenzo Galluzzi,Fabrice Andre,Fabrice Andre,Laurence Zitvogel +5 more
TL;DR: It is pointed out that the successful implementation of immunotherapy to BC management requires the optimization of current immunotherapeutic regimens and the identification of immunological biomarkers that enable improved risk stratification and the design of personalized, dynamic treatment plans.